Special Issue "Inflammation, Immunity, and Cancer Progression"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 15 March 2023 | Viewed by 379

Special Issue Editors

Dr. Deepak Parashar
E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
Interests: noncoding RNA; cancer metabolism; tumor microenvironment (TME); exosome; cancer stemness and chemoresistance
Dr. Vivek K. Kashyap
E-Mail Website
Guest Editor
Department of Immunology and Microbiology, South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, USA
Interests: basic mechanisms of cancer progression, health disparities, pre-clinical drug development; miRNA; lncRNAs; snoRNAs; nano-technology therapies; antibody-drug conjugates, and exosome-mediated drug delivery
Dr. Subhash Tripathi
E-Mail Website
Guest Editor
Seattle Children's Research Institute, Seattle, WA, USA
Interests: cancer immunology; inflammation and autoimmunity; molecular immunology; developmental immunology; gene editing and cell therapy

Special Issue Information

Dear Colleagues,

Chronic inflammation plays a significant role in cancer initiation, progression, metastasis, and chemoresistance.  Additionally, cancer-related inflammation is the seventh hallmark of cancer and is associated with genetic instability. Genomic and epigenomic mechanisms are essential to establishing cellular programs in cancer and immune cells. The dysregulation of these mechanisms contributes to tumor growth. Transcriptional and epigenetic changes during inflammatory conditions have revealed histone modifications and transcriptional signatures that define dysregulation of cellular function in cancer and immune cells. Eventually, discovering a core set of regulators, such as transcription factors, epigenetic regulatory molecules, and signaling molecules, that can regulate functions in these cells may be sufficient to help reprogram terminally differentiated immune cells. Such findings are certainly having an impact on immune cell-based therapies.

Recent advances in cancer and immune cell genomics and immune cell engineering have therapeutic implications and provide discourse on the challenges, perspectives, and outstanding questions for the emerging role of transcriptional, epigenetic, and metabolic regulation in cancer and immunity.

This Special Issue will highlight the latest experimental advances and technical developments in genomics and epigenomics, gene editing, gene delivery, and therapeutic approaches for studying immune regulation in immune-mediated diseases, including autoimmunity and cancer. The goal is to cover this broad field through a series of high-quality, multidisciplinary research articles discussing overlapping subjects in transcriptional and epigenetic regulation of inflammation during cancer and immunity. We will consider original research, methodology, review articles, and short reports.

Manuscript submissions presenting outstanding contributions to cancer and immunity fields, including, but not limited to, the following topics:

  • Inflammation in cancer immunity;
  • Transcriptional and epigenetic regulations in cancer cells and immune cell differentiation and development;
  • Transcriptomics and epigenomics of immune-mediated diseases;
  • Immunometabolism;
  • Pharmacogenomic of diseases;
  • Integration of Bioinformatics Data.

Dr. Deepak Parashar
Dr. Vivek K. Kashyap
Dr. Subhash Tripathi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • inflammation
  • cancer immunity
  • transcriptomics
  • epigenomics
  • immunometabolism
  • pharmacogenomic
  • bioinformatics data
  • immunopharmacogenomics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Caerin 1.1/1.9 Enhances Antitumour Immunity by Activating the IFN-α Response Signalling Pathway of Tumour Macrophages
Cancers 2022, 14(23), 5785; https://doi.org/10.3390/cancers14235785 - 24 Nov 2022
Viewed by 141
Macrophages are one of the essential components of the tumour microenvironment (TME) of many cancers and show complex heterogeneity and functions. More recent research has been focusing on the characterisation of tumour-associated macrophages (TAMs). Previously, our study demonstrated that caerin 1.1/1.9 peptides significantly [...] Read more.
Macrophages are one of the essential components of the tumour microenvironment (TME) of many cancers and show complex heterogeneity and functions. More recent research has been focusing on the characterisation of tumour-associated macrophages (TAMs). Previously, our study demonstrated that caerin 1.1/1.9 peptides significantly improve the therapeutic efficacy of combined specific immunotherapy and immune checkpoint blockade in a murine transplantable tumour model (TC-1). In this study, the mice inoculated with TC-1 tumour were immunised differently. The TAMs were isolated using flow cytometry and characterised by cytokine ELISA. The survival rates of mice with different treatments containing caerin 1.1/19 were assessed comparatively, including those with/without macrophage depletion. The single-cell RNA sequencing (scRNA-seq) data of previous studies were integrated to further reveal the functions of TAMs with the treatments containing caerin 1.1/1.9. As a comparison, the TAMs of stage I and II cervical cancer patients were analysed using scRNA-seq analysis. We demonstrate that caerin induced tumour clearance is associated with infiltration of tumours by IL-12 secreting Ly6C+F4/80+ macrophages exhibiting enhanced IFN-α response signalling, renders animals resistant to further tumour challenge, which is lost after macrophage depletion. Our results indicate that caerin 1.1/1.9 treatment has great potential in improving current immunotherapy efficacy. Full article
(This article belongs to the Special Issue Inflammation, Immunity, and Cancer Progression)
Show Figures

Figure 1

Back to TopTop